Findings from the 16th wave of Spherix Global Insights’ COVID-19 research indicate that telemedicine is firmly entrenched, industry interaction remains...
While early patterns suggest that Genentech’s Ocrevus largely evades newcomer Novartis’ Kesimpta, COVID-19-related shifts in prescribing may be the real...
Six pipeline product profiles were evaluated by current inflammatory bowel disease treaters to assess strengths, weaknesses, and potential prescribing levels...
Spherix announces the release of three new research publications in its RealWorld Dynamix™ series, revealing patient types, treatment paradigms, and...
According to Spherix Global Insights, nephrologists and rheumatologists express measured optimism about these treatment options and seek more experience with...
According to new research published by Spherix Global Insights, the CKD non-dialysis market is poised for seismic shifts as SGLT2...
Managed care decisions will likely have a substantial impact on shaping rheumatologists’ future IL-17 preference, according to Spherix Global Insights...
Company continues to post strong growth despite pandemic distraction EXTON, Pa., February 16, 2021 /PRNewswire/ — Spherix Global Insights (“Spherix”)...
According to Spherix Global Insights, the emerging Bruton’s tyrosine kinase inhibitors, including EMD Serono’s evobrutinib, Sanofi Genzyme’s tolebrutinib, and Genentech’s...
According to Spherix Global Insight’s COVID-19 tracker, dermatologists and rheumatologists alike report that they are more inclined to use Otezla...
The Launch Dynamix™ service includes current tracking of Cosentyx (Novartis) and Taltz (Eli Lilly) in non-radiographic axial spondyloarthritis, Kesimpta (Novartis)...
According to Spherix Global Insights, rheumatologists and nephrologists are excited about new treatment options in addition to a multitude of...
